louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05897671: Foveal Sparing ILM Peeling With ILM Flap Transposition
Official title: Foveal Sparing ILM Peeling With ILM Flap Transposition
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Full Thickness Macular Hole
Lead sponsor: Vienna Institute for Research in Ocular Surgery
Sponsor class: OTHER
First posted: 2023-06-09
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The participants will be selected by the clinical investigators in the Hanusch Hospital

Brief summary: Foveal sparing internal limiting membrane (ILM) peeling with ILM flap transposition over the macular hole combines the benefits of foveal sparing ILM peeling with ILM flap techniques.

Aim of this study is to retrospectively examine the rate of postsurgical macular hole closure, development of central atrophy in the foveal area, and improvement of best corrected distant visual acuity in a group of patients having undergone foveal sparing ILM peeling with ILM flap transposition for macular hole repair.

Detailed description: Idiopathic full thickness macular holes lead to central defects in the visual field and to deterioration of the visual acuity. Introduction of internal limiting membrane (ILM) Peeling techniques lead to significant increase in closure rates of the macular holes.

Foveal sparing ILM peeling represents a surgical technique for macular hole repair with less surgical trauma with high closure rates of the macular hole, compared to classic ILM Peeling \[Ho et al. 2014, Murphy et al 2019\]. The combination of foveal sparing ILM Peeling with the established ILM flap techniques \[Michalewska et al 2010 und 2015\] offers the potential of better improvement in postsurgical visual acuity with the high closure rates, due to ILM flaps.

Aim of this study is to retrospectively examine the rate of postsurgical macular hole closure, development of central atrophy in the foveal area, and improvement of best corrected distant visual acuity in a group of patients having undergone foveal sparing ILM peeling with ILM flap transposition for macular hole repair.

Eligibility criteria: Inclusion Criteria:

* Vitrectomy with foveal sparing ILM peeling with ILM flap transposition in the time period from 1.10.2020 to 8.7.2022
* Age 18 and older
* Idiopathic full thickness macular hole as indication for surgery
* Full follow-up, including visual acuity testing and OCT preoperative, and 3 months after surgery.

Exclusion Criteria:

* Age \<18 years

Primary outcomes:
measure: macular hole closure rate
timeFrame: up to 3 months after surgery
Secondary outcomes:
measure: visual acuity
timeFrame: 3 months
measure: OCT
timeFrame: 3 months
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Hanusch Hospital, Department of Ophthalmology
Study officials:
affiliation: head of departement
name: Oliver Findl, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02951871: Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis
Official title: Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: This Study Describes the Different Causes of Death in 237 FL Patients
Keywords: Follicular lymphoma; death, rituximab, treatment related toxicity
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-11-01
Enrollment: 237
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This retrospective analysis was performed in 3 reference center where patients were treated and regularly followed for FL between January 2000 and December 2015. All patients were initially staged according to the conventional recommendations, including a clinical examination and blood tests, a bone marrow biopsy, and a computerized tomography body scan. The treatment modalities have evolved over time and were chosen according to the institutional guidelines.

Brief summary: Background.Although the life expectancy of patients with FL has recently increased, notably since the introduction of rituximab in combination with chemotherapy, little is known regarding the precise causes of patients death. Patients and methods'. This study describes the different causes of death in FL patients among followed since 2000 at Lyon University Hospital, centre Léon Bérard and Mayo Clinic. The causes of death will be classified as related to lymphoma progression, treatment-related toxicity (including TRM and secondary myelodysplastic syndrome/acute myeloid leukemia), secondary neoplasias, or other.


Eligibility criteria: Inclusion Criteria:

* FL patients
* patients recorded as deceased

Exclusion Criteria:

-Other diagnosis than FL

Primary outcomes:
measure: overall survival (OS)
timeFrame: OS length was calculated from the date of diagnosis to the date of death
Secondary outcomes:
Other outcomes:
Locations:
city: Pierre Bénite
country: France
facility: Centre hospitalier Lyon sud
state: Rhône Alpes
Study officials:
References:
Clinical trial NCT01012271: Diagnostic Accuracy of Direct MR Arthrography Of The Wrist At 1.5, 3.0 And 7.0T
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Wrist Injuries
Keywords: Wrist abnormalities
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2009-11-13
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: primary care clinic

Brief summary: The purpose of our study is to evaluate the diagnostic accuracy of MR arthrography of the wrist at 1.5, 3.0, and 7.0T with wrist arthroscopy as reference standard.


Eligibility criteria: Inclusion criteria:

* age \>18;
* clinical evidence for wrist joint abnormalities;
* request for MR arthrography prior to wrist arthroscopy;
* willingness to take part in our study with written informed consent;

Exclusion criteria:

* age\<18;
* history of prior wrist surgery; systemic diseases e.g. rheumatoid arthritis;
* infection; history of adverse contrast reactions;
* contraindication for MR imaging (e.g. pacemaker, metallic implants, etc.);
* history or possible signs of renal failure (see section "nephrogenic systemic fibrosis")

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
Clinical trial NCT04838171: Prospective Study of White Blood Cells
Official title: Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Autoimmune Diseases
Inflammation
Rejection; Transplant, Liver
Lead sponsor: Quell Therapeutics Limited
Sponsor class: INDUSTRY
First posted: 2021-04-08
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Volunteers willing to provide white blood cells for research.

Brief summary: The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.


Eligibility criteria: No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.

Primary outcomes:
measure: WBC characterisation to support the development of engineered regulatory T cells.
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Quell Investigator Site 01
Study officials:
References:
Clinical trial NCT00201071: Asthma Surveillance and Education in Preschool Settings
Official title: Asthma Surveillance and Education in Preschool Settings
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sponsor class: NIH
First posted: 2005-09-20
Enrollment: 208
Sex: ALL
Minimum age (years): 2
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We formed collaborative agreements with subsidized day care providers in three New York City communities with high asthma prevalence. These three communities - Harlem, the South Bronx and the Lower East Side - are economically disadvantaged communities of color. Participants were parents or guardians of children with asthma enrolled in subsidized day care center. 95% of participants were female, 64% were Hispanic, 25% were Black, 1% were White and 10% were Other. 70% were born in the continental USA, 70% spoke English as their primary language. 30% had earned less than a HS degree, 32% had received a HS diploma or a GED, 37% had attended som college, and 1% had completed college. 33% of participants had family incomes of less than $1,000 per month, 35% had incomes of $1,000 to $1,999 and 32% had incomes over $2,000.

Brief summary: The purpose of this study is to test the effectiveness of a bilingual intervention in improving asthma care for low-income inner-city children enrolled in subsidized preschool childcare programs.

Detailed description: BACKGROUND:

Proposed is a non-randomized, controlled, prospective trial to test the efficacy of a bilingual intervention to improve asthma care for low-income inner-city children enrolled in subsidized preschool childcare programs. Because of high rates of asthma prevalence, subsidized preschool childcare programs offer ideal settings to test innovative strategies to improve asthma care within communities at highest risk of morbidity.

DESIGN NARRATIVE:

The study will comprise three arms. Arm 1 is surveillance, in which children with asthma are identified. In Arm 2, children with asthma are identified and given written Asthma Action Plans (monitoring). Arm 3 consists of surveillance, monitoring, and education.

Eligibility criteria: Inclusion Criteria:

* Enrolled in specific subsidized preschools in New York City
* 2.8 to 4 years old
* Persistent asthma as defined by symptom reports
* Use of quick-relief agents or controller medications

Exclusion Criteria:

* History of intubation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: The New York Academy of Medicine, CUES
state: New York
Study officials:
affiliation: The New York Academy of Medicine, CUES
name: Sebastian Bonner, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03790371: Vaginal Misoprostol Before Intrauterine Contraceptive Device Insertion
Official title: Vaginal Misoprostol Before Intrauterine Contraceptive Device Insertion Following Previous Insertion Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Contraception
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2018-12-31
Enrollment: 90
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the current study was conducted to assess efficacy of vaginal misoprostol before IUD insertion following previous insertion failure


Eligibility criteria: Inclusion Criteria:

One previous failed attempt of IUD insertion.

Exclusion Criteria:

1. Uterine fibroid distorting the cavity.
2. Anatomical uterine abnormality with distortion of the cavity
3. Current pelvic inflammatory disease or recently treated pelvic inflammatory disease (PID) in the last three months.
4. Current purulent cervicitis (chlamydia or gonorrhea).
5. Immediately after septic abortion.
6. Uterus size less than 6 cm and more than 9 cm.

Primary outcomes:
measure: the success rate for IUD insertion.
timeFrame: four hours after misoprostol dose
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: AinShams university maternity hospital
state: Abbassya
Study officials:
References:
Clinical trial NCT00971971: Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients
Official title: Assessment of a Protocol Aiming to Prevent Intradialytic Hypotension in Critically Ill Acute Kidney Injury Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Kidney Injury
Acute Renal Failure
Keywords: Hypotension
Acute renal failure
acute kidney injury
dialysis
ICU
Lead sponsor: Sao Jose do Rio Preto Medical School
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2009-09-04
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Intradialytic hypotension (IH) is a major complication during acute hemodialysis. The aim of this study was to evaluate the effects of dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling on hemodynamics of critically ill acute kidney injury (AKI) patients submitted to sustained low-efficiency dialysis (SLED).


Eligibility criteria: Inclusion Criteria:

* Acute renal failure with a need of dialysis.

Exclusion Criteria:

* Patients with basal serum creatinine \> 3 mgdL.
* Patients submitted to renal transplantation.
* Patients unlikely to survive.
* Declination in authorization to participation in the study.

Primary outcomes:
measure: Intradialytic hypotension
timeFrame: At dialysis session
Secondary outcomes:
measure: Dialysis dose
timeFrame: dialysis session
Other outcomes:
Locations:
city: Sao Jose do Rio Preto
country: Brazil
facility: São Jose do Rio Preto Medical School
state: SP
Study officials:
References:
Clinical trial NCT00510471: Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
Official title: A Phase 2 Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With Follicular Non-Hodgkin's Lymphoma (fNHL) Following Primary Treatment With Rituximab and Chemotherapy (R-Chemo)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Non-Hodgkin's Lymphoma
Lead sponsor: Genitope Corporation
Sponsor class: INDUSTRY
First posted: 2007-08-02
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The treatment being investigated is a patient- and tumor-specific therapy known as a personalized active immunotherapy. Personalized active immunotherapy is an attempt to use a person's own immune system to combat disease. Sargramostim (a.k.a. GM-CSF) is given together with the personalized active immunotherapy because it may increase the immune system's response and, therefore, aid in the effect of the personalized active immunotherapy.

This approach has previously been studied in patients with follicular Non-Hodgkin's lymphoma and other B-cell malignancies. Encouraging efficacy results and a favorable safety profile have been seen to date in these studies.


Eligibility criteria: Inclusion Criteria:

1. Written informed consent
2. Previously untreated follicular NHL
3. Stage III or IV disease requiring treatment
4. Able to receive rituximab and chemotherapy (rituximab with cyclophosphamide, vincristine, and prednisone either with or without doxorubicin)
5. Able to provide tumor sample adequate for Id-KLH manufacture
6. ≥ 18 years of age
7. At least one bi-dimensionally measurable lesion ≥ 2 cm by CT scan

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Keck School of Medicine of University Southern California
state: California
city: Denver
country: United States
facility: Rocky Mountain Cancer Centers
state: Colorado
city: Indianapolis
country: United States
facility: Indiana University Medical Center
state: Indiana
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Omaha
country: United States
facility: University of Nebraska Medical Center
state: Nebraska
city: New York
country: United States
facility: Weill Medical College of Cornell University, NY Presbyterian Hospital
state: New York
city: Charlotte
country: United States
facility: Carolinas Medical Center
state: North Carolina
city: Oklahoma City
country: United States
facility: University of Oklahoma Health Science Center
state: Oklahoma
city: Portland
country: United States
facility: Providence Portland Cancer Center
state: Oregon
Study officials:
References:
Clinical trial NCT00193271: Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Official title: Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
Collaborators: name: Aventis Pharmaceuticals
First posted: 2005-09-19
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.

Detailed description: Upon determination of eligibility, patients will receive:

Docetaxel + Estramustine

Eligibility criteria: Inclusion Criteria:

To be included in this study, you must meet the following criteria:

* Histologically confirmed adenocarcinoma of the prostate
* Clinically or surgically staged localized disease, stage I-III.
* Prior surgical resection or radiation therapy with curative intent
* No clinical evidence of residual disease
* Gleason's combined score \> 7.
* Age \> 18 years.
* No prior chemotherapy for prostate cancer.
* No previous androgen deprivation therapy for prostate cancer
* Able to perform activities of daily living with minimal assistance
* Adequate bone marrow, liver and kidney function
* Voluntarily provide written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

* History of prior malignancy in the past five years
* History of significant heart disease within the previous 6 months
* Cerebral vascular accident (CVA) or stroke within the previous 6 months.
* Moderate or severe peripheral neuropathy
* Previous therapy with other injectable radioisotopes.

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Primary outcomes:
measure: Response Rate
Secondary outcomes:
measure: Rate of recurrence
measure: Toxicity
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
Study officials:
affiliation: SCRI Development Innovations, LLC
name: Anthony A. Meluch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04905771: Characterizing Follicles From Auto-transplanted Ovarian Tissue
Official title: Characterizing Follicles From Auto-transplanted Ovarian Tissue
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Infertility, Female
Keywords: Infertility
Lead sponsor: Regionshospitalet Viborg, Skive
Sponsor class: OTHER
Collaborators: name: Reproduktionsbiologisk Laboratorium, JMC, Rigshospitalet, København
First posted: 2021-05-28
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 30 women undergoing fertility treatment who has had frozen and later autotransplanted ovarian tissue for fertility preservation purposes

Brief summary: The aim of the project is to characterize the hormonal conditions in egg follicles in women who, prior to fertility treatment, have had autotransplanted frozen ovarian tissue for the purpose of fertility preservation.


Eligibility criteria: Inclusion Criteria:

* Women aged 18 years or older
* Has had frozen and later autotransplanted ovarian tissue for fertility preservation purposes
* Included in fertility treatment with eff retrieval at the Fertility Clinic Regional Hospital Skive
* Is willing and able to give informed consent

Exclusion Criteria:

- Patients undergoing fertility treatment but have not received autotransplanted ovarian tissue for fertility preservation purposes

Primary outcomes:
measure: Characterize hormone production in follicles from autotransplanted ovarian tissue
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Skive
country: Denmark
facility: Fertility Clinic, Skive Regional Hospital
Study officials:
References:
Clinical trial NCT01633671: NT-proBNP as a Tool for the Detection of Acute Pulmonary Artery Embolism (APE)
Official title: NT-proBNP: a Useful Tool for the Detection of Acute Pulmonary Artery Embolism in Post-surgical Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Embolism
Pulmonary Embolism Without Mention of Acute Cor Pulmonale
Keywords: Misadventures to Patients During Surgical and Medical Care
Pulmonary Embolism Without Acute Cor Pulmonale
Pulmonary Embolism Without Mention of Acute Cor Pulmonale
Lead sponsor: University of Ulm
Sponsor class: OTHER
First posted: 2012-07-04
Enrollment: 44
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients after major surgery referred to the anesthesiologic ICU due to suspected acute pulmonary embolism.

Brief summary: In patients with suspected APE (Acute Pulmonary Embolism) referred to the intensive care unit (ICU)after major surgery, serum NT-proBNP (N-terminal proBNP), Troponin-I and D-dimers were measured according to the standard hospital protocol. To definitively confirm or exclude APE, all patients underwent an angiographic CT-scan of the thorax.

Detailed description: In patients with suspected APE referred to the intensive care unit after major surgery, serum NT-proBNP, Troponin-I and D-dimers were measured according to the standard hospital protocol. Blood samples were obtained within one hour after the onset of clinical symptoms.

Definitive confirmation or exclusion of APE was performed with an angiographic CT-scan of the thorax.

Eligibility criteria: Inclusion Criteria:

all patients referred to the ICU with suspected APE

Exclusion Criteria:

none

Primary outcomes:
measure: Acute pulmonary embolism: CT-proof yes vs. no
timeFrame: 1 hour after onset of clinical symptoms
Secondary outcomes:
Other outcomes:
Locations:
city: Ulm
country: Germany
facility: University of Ulm, Michelsberg anaesthesiologic ICU
state: Baden-Wuerttemberg
Study officials:
affiliation: Dept. of Anesthesiology, Div. of Emergency medicine, University hospital Ulm, 89075 Ulm, Germany
name: Claus M Muth, MD
role: STUDY_CHAIR
affiliation: Dept. of Anesthesiology, University hospital Ulm, 89075 Ulm, Germany
name: Bernd E Winkler, MD
role: PRINCIPAL_INVESTIGATOR
References: